263 related articles for article (PubMed ID: 32944843)
1. Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study.
Ford JH; Stauffer VL; McAllister P; Akkala S; Sexson M; Ayer DW; Wang S
Qual Life Res; 2021 Feb; 30(2):455-464. PubMed ID: 32944843
[TBL] [Abstract][Full Text] [Related]
2. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
[TBL] [Abstract][Full Text] [Related]
3. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).
Ford J; Tassorelli C; Leroux E; Wang S; Ayer D; Nichols R; Detke H
Qual Life Res; 2021 Jan; 30(1):105-115. PubMed ID: 32930994
[TBL] [Abstract][Full Text] [Related]
4. Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis.
Ailani J; Andrews JS; Tockhorn-Heidenreich A; Wenzel R; Rettiganti M
Adv Ther; 2022 Oct; 39(10):4544-4555. PubMed ID: 35930126
[TBL] [Abstract][Full Text] [Related]
5. Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.
Varnado OJ; Ye W; Mi X; Burge R; Hall J
J Med Econ; 2023; 26(1):149-157. PubMed ID: 36601798
[TBL] [Abstract][Full Text] [Related]
6. Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).
Tepper SJ; Ailani J; Ford JH; Nichols RM; Li LQ; Kemmer P; Hand AL; Tockhorn-Heidenreich A
Clin Drug Investig; 2022 Mar; 42(3):263-275. PubMed ID: 35041159
[TBL] [Abstract][Full Text] [Related]
7. Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.
Ford JH; Ayer DW; Zhang Q; Carter JN; Leroux E; Skljarevski V; Aurora SK; Tockhorn-Heidenreich A; Lipton RB
Neurology; 2019 Jul; 93(5):e508-e517. PubMed ID: 31270220
[TBL] [Abstract][Full Text] [Related]
8. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
[TBL] [Abstract][Full Text] [Related]
9. Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study.
Zhou J; Zhong L; Chowdhury D; Skorobogatykh K; Luo G; Yang X; Zhang M; Sun L; Liu H; Qian C; Yu S
J Headache Pain; 2023 Aug; 24(1):103. PubMed ID: 37542222
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
12. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
[TBL] [Abstract][Full Text] [Related]
13. Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study.
Shibata M; Nakamura T; Ozeki A; Ueda K; Nichols RM
J Pain Res; 2020; 13():3531-3538. PubMed ID: 33408512
[TBL] [Abstract][Full Text] [Related]
14. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
Camporeale A; Kudrow D; Sides R; Wang S; Van Dycke A; Selzler KJ; Stauffer VL
BMC Neurol; 2018 Nov; 18(1):188. PubMed ID: 30413151
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
Ruff DD; Ford JH; Tockhorn-Heidenreich A; Sexson M; Govindan S; Pearlman EM; Wang SJ; Khan A; Aurora SK
Cephalalgia; 2019 Jul; 39(8):931-944. PubMed ID: 31104507
[TBL] [Abstract][Full Text] [Related]
16. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
Ailani J; Andrews JS; Rettiganti M; Nicholson RA
J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
[TBL] [Abstract][Full Text] [Related]
17. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
[TBL] [Abstract][Full Text] [Related]
18. A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist.
Kudrow D; Nguyen L; Semler J; Stroud C; Samaan K; Hoban DB; Wietecha L; Hsu HA; Pearlman E
Headache; 2022 Oct; 62(9):1164-1176. PubMed ID: 36111429
[TBL] [Abstract][Full Text] [Related]
19. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
Lipton RB; Tepper SJ; Reuter U; Silberstein S; Stewart WF; Nilsen J; Leonardi DK; Desai P; Cheng S; Mikol DD; Lenz R
Neurology; 2019 May; 92(19):e2250-e2260. PubMed ID: 30996060
[TBL] [Abstract][Full Text] [Related]
20. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
Ambrosini A; Estemalik E; Pascual J; Rettiganti M; Stroud C; Day K; Ford J
J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
[No Abstract] [Full Text] [Related]
[Next] [New Search]
